1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Camurus AB

Camurus AB

CAMRF
Camurus ABUS flagOther OTC
60.00
USD
-1.01
- -
3.60BMarket Cap
Camurus AB
CAMRF
(Other OTC)

Recent

price

60.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
2.33
4.83
5.09
5.35
2.79
1.33
1.21
2.27
6.38
11.03
17.37
30.95
32.2
38.24
38.56
Revenue per Share
- -
0.33
2.43
1.18
-5.51
-1.99
-4.68
-5.77
-6.23
-3.18
-1.66
1.01
7.78
7.39
12.42
12.22
Basic EPS, GAAP
- -
0.48
3.62
1.52
-0.24
-5.21
-5.04
-6.86
-9.25
-4.6
-2.72
1.8
10.76
6.18
12.34
10.53
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.16
0.4
1.58
0.5
-1.64
-6.32
-12.09
-16.8
-18.03
-19.07
-17.86
-9.95
-2.13
10.33
5.42
Book Value per Share
- -
0.8
0.72
2.47
21.41
13.4
9.05
5.81
12.78
15.39
14.97
17.63
26.5
56.32
71.14
65.48
Tangible Book Value per Share
- -
41
41
41
29
41
41
41
46
53
54
55
55
58
59
59
Basic Weighted Avg Shares
- -
95
198
208
155
114
54
49
106
336
601
956
1,717
1,868
2,265
2,267
Sales/Revenue/Turnover
- -
21.24
61.69
28.77
-131.43
-90.68
-446.3
-583.48
-340.98
-61.48
-18.71
7.45
31.07
24.83
38.58
37.01
Operating Margin (%)
- -
1
1
1
4
4
4
4
9
12
13
13
14
15
25
19
Depreciation Expense
- -
13
99
48
-160
-81
-191
-235
-290
-167
-90
56
431
428
736
718
Net Income, GAAP
- -
25.44
22.03
22.7
- -
- -
- -
- -
- -
- -
- -
24.03
21.46
22.47
21.17
21.28
Effective Tax Rate (%)
- -
13.99
50.19
23.22
-103.06
-71.21
-350.91
-475.81
-274.48
-49.78
-15.06
5.81
25.13
22.94
32.47
31.69
Profit Margin (%)
-3
32
30
102
574
474
243
54
322
492
466
634
1,255
3,110
4,071
3,716
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
23
20
19
17
14
7
86
85
LT Debt
12
40
50
123
641
564
385
252
632
847
849
995
1,493
3,290
4,235
3,871
Total Equity
- -
58.26
210.74
50.45
- -
- -
- -
- -
- -
- -
- -
5.67
32.75
14.82
17.93
18.95
Return on Invested Capital (%)
- -
-180.76
862.87
119.32
- -
- -
- -
- -
- -
- -
- -
-5.73
-58.25
-135.38
242.06
3,333.8
Return on Capital (%)
- -
- -
862.05
119
-402.89
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
10
19
19
LT Borrowings
- -
- -
- -
LT Finance Leases
7
87
85
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
59
59
59
Market Capitalization
32,918
35,349
35,199

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
3,549
3,678
4,177
Cash, Cash Equivalents & STI
2,853
2,878
3,347
Accounts Receivable, Net
416
509
511
Inventories
140
134
124
Total Current Liabilities
439
389
461
Payables & Accruals
- -
- -
- -
ST Debt
10
19
19
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
32.29%
43.31%
28.75%
Free Cash Flow
333.77%
71.84%
103.78%
Net Income, GAAP
63.07%
108.05%
71.7%
Sales/Revenue/Turnover
49.19%
49.52%
21.3%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
390
445
480
553
1,868
2025
558
676
464
- -
2,265
2026
533
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.36
1.28
2.21
2.5
7.39
2025
3.36
4.15
1.69
- -
12.42
2026
2.42
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Auro Laboratories Limited (AUROLAB.BO)
Ji Yao Holding Group Co., Ltd. (300108.SZ)
Oxurion N.V. (0G99.L)
BioArctic AB (publ) (BRCTF)
MDxHealth S.A. (0O8G.L)
Sibannac, Inc. (SNNC)
Business
Camurus AB (publ) (Nasdaq Stockholm: CAMX) is a Swedish science-led biopharmaceutical company that develops and commercializes innovative, long-acting medicines for patients with severe and chronic diseases, including opioid dependence, pain, cancer, endocrine disorders, rare diseases and supportive care; the company leverages its proprietary FluidCrystal drug delivery technology platform to create sustained-release formulations such as weekly and monthly subcutaneous depots. Core products on the market include Buvidal (buprenorphine prolonged-release injection) for opioid dependence, marketed in Europe, Australia and other regions through commercial partnerships; Brixadi (buprenorphine) extended-release subcutaneous injection for opioid use disorder in the US, distributed by partner Braeburn Pharmaceuticals; and Oczyesa (octreotide subcutaneous depot) for acromegaly and neuroendocrine tumours. The clinical pipeline features candidates like CAM2029 (octreotide depot) in phase 3 for neuroendocrine tumours and acromegaly, CAM2056 (semaglutide monthly depot) with positive topline phase 1 data for cardiometabolic diseases, CAM2038 (buprenorphine depot) for chronic pain, and programs in oncology and rare diseases developed in-house or with partners. Founded in 1991 and headquartered in Lund, Sweden, Camurus employs over 275 people with regional offices in the UK, Germany, Australia and the US; it operates primarily in Europe, North America and Australia. Recent developments include EU and UK approvals for Oczyesa in acromegaly (July 2025), UK launch of Oczyesa (November 2025), a June 2025 license and collaboration agreement with Eli Lilly for long-acting FluidCrystal incretins in cardiometabolic disease (with up to SEK 870m milestones plus royalties, excluding Camurus' independent semaglutide program), positive topline results from the CAM2056 phase 1 study (November 2025), and POSITANO phase 2b data for CAM2029 in polycystic liver disease (June 2025).

Company News

APIChatGPT

  • reuters.com

    Camurus' hormone disorder drug expected to be approved in 2027 after fresh FDA setback

  • prnewswire.com

    Camurus announces expansion of Lilly collaboration

  • seekingalpha.com

    Camurus AB (publ) (CAMRF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Camurus AB (publ) (CAMRF) Q3 2025 Earnings Call Transcript

  • prnewswire.com

    Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

  • reuters.com

    US FDA declines to approve Camurus' rare hormone disorder drug

  • prnewswire.com

    New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl